Default company panoramic image

BioSensors Inc

BioSensors is a 100% non-invasive continuous glucose monitor offering measurements from the body’s surface without penetration of the skin.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Schenectady, NY, USA
  • Currency USD
  • Founded January 2009
  • Employees 5
  • Website

Company Summary

BioSensors, Inc. is currently a research and development company which seeks to gain growth and economic return through the licensing or sale of proprietary technology. The initial customers for the diabetes glucose monitor technology are the large international biomedical equipment and pharmaceutical companies. Diabetes affects 246 million people and patients with this disease face frequent use of painfull invasive methods to monitor glucose.


  • Default avatar
    David Harry Apkarian
    President and CEO

    Employed by TransTech (BioSensors parent company) for 15 years; BA Davenport University. Mr. Apkarian was elected President of TransTech in October 2005 and of BioSensors in 2009. He has spearheaded the internationalization and development of TransTech. Mr. Apkarian has extensive experience in sales, marketing, strategic and tactical implementation with TransTech in relation to its products, laboratory services and research and development.

  • Default avatar
    Chester Opalka

    Mr. Opalka is a co-founder of Albany Molecular Research, Inc. (AMRI), a full-service chemistry services company focused on applications for the pharmaceutical, biotechnology and life sciences industries. The company, founded in 1991, is based in Albany, NY. He retired from the daily operations of the company in September 2000. He retired from the board of directors in May 2002. Prior to founding AMRI, Mr. Opalka worked for Sterling Drug Inc.

  • Default avatar
    Donald Colosimo
    General Manager

    BS and MS from MTI and MBA from SUNY at Buffalo. Prior to joining TransTech, Mr. Colosimo was president and owner of Comtel, Inc., a technical products distribution and technical services company with 120 employees in nine offices covering 15 states. Mr. Colosimo has experience in the conduct, management and marketing of R&D programs. He was manager of business development for a number of companies engaged in intellectual property licensing.

  • Default avatar
    Sarah E. Pluta
    Senior Scientist

    BS and MS from RPI; Ms. Pluta is the principal investigator and the primary inventor for the SEMP technology. She is the technical leader on the SEMP technology development. Her contributions include development of surface sensor measurement fixtures, conduct of the in-vitro tests, development of the equivalent circuit models, the EIT mathematical model, and the design of the prototype to be used in human testing.

  • Default avatar
    Matthew Cusack
    VP of Operations

    20 years of experience; specialties in manufacturing, launching technologies in the clinical/pre-clinical medical device market.